What to Know Before AAD 2025: Product Snapshots of Nonsteroidal Topical Treatments for Eczema
They are a Janus kinase (JAK)1/JAK2 inhibitor, a phosphodiesterase-4 inhibitor, and an investigational aryl hydrocarbon receptor agonist. Learn more about each.
Atopic Dermatitis Primer for AAD 2025: Dermatologist Mona Shahriari, MD, Explains the Rise in Prevalence
Shahriari, assistant clinical professor of dermatology at Yale University School of Medicine, says greater understanding of the condition has expanded the population for the diagnosis.
American Academy of Dermatology 2025 Prep: A Dermatologist Considers When Atopic Dermatitis Referral from Primary Care is Indicated
Up to 80% of atopic dermatitis is managed in primary care but some patients will need a higher level of care. Dr Mona Shahriari discusses factors that point to referral.
Focus on AAD 2025: Dermatologist Mona Shahriari, MD, Highlights the PCP Role in Atopic Dermatitis Care
Not all atopic dermatitis requires treatment by a specialist, says this dermatologist, and she collaborates regularly with her primary care colleagues.
Expert Perspectives 2024: Nonsteroidal Topicals for Atopic Dermatitis with Mona Shahriari, MD
The new nonsteroidal topical treatments for atopic dermatitis are targeted and modify the disease process, explains thought leader Shahriari in this year's video series.
When is It Time to Refer? A Dermatologist Considers Atopic Dermatitis Treated in Primary Care
Nonsteroidal Topical Treatments for Eczema: A Product Snapshot with Mona Shahriari, MD
Dermatologist Mona Shahriari, MD, Relies on Primary Care Colleagues as First-Line Prescribers for AD
Why is Atopic Dermatitis Prevalence Rising? Dermatologist Mona Shahriari, MD, Parses the Trends